Macrolide-resistant Mycoplasma pneumoniae pneumonia in transplantation: Increasingly typical?

Gregory A Eschenauer1, Li Xiao2, Ken B Waites3

  • 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.

Insights

Macrolide-resistant Mycoplasma pneumoniae (MRMP) can cause severe pneumonia, especially in immunocompromised individuals. Alternative antibiotics like fluoroquinolones or tetracyclines are effective when macrolides fail.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology

Background:

  • Mycoplasma pneumoniae is a common cause of pneumonia.
  • Macrolide-resistant M. pneumoniae (MRMP) accounts for 7.5% of isolates in the US.
  • Resistance to macrolides necessitates alternative treatment strategies.

Purpose of the Study:

  • To highlight the clinical significance of MRMP in immunocompromised patients.
  • To present cases of MRMP pneumonia in kidney transplant recipients.
  • To emphasize the importance of considering non-macrolide therapies.

Main Methods:

  • Case report of two kidney transplant recipients with MRMP pneumonia.
  • Multiplex respiratory pathogen panel analysis of BAL fluid.
  • Real-time PCR and molecular genotyping to confirm resistance and identify strains.

Main Results:

  • Both patients experienced worsening symptoms on macrolide therapy.
  • Rapid defervescence was observed after treatment with doxycycline or levofloxacin.
  • Molecular analysis confirmed macrolide resistance and identical genotypes in both cases.

Conclusions:

  • Clinicians must be aware of potential macrolide resistance in M. pneumoniae.
  • Non-macrolide therapies should be considered for confirmed or unresponsive M. pneumoniae infections, particularly in hospitalized or immunocompromised patients.